Cue Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2021 Annual Meeting of Stockholders held on June 9, 2021. Cue Biopharma, Inc. is a Delaware corporation listed on the Nasdaq Capital Market under the symbol CUE. The company is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on the election of directors and the ratification of the independent auditor. All seven director nominees were elected. The appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
| Director Nominee | For Votes | Withheld Votes | Broker Non-Votes |
|---|---|---|---|
| Frederick Driscoll | 9,461,702 | 3,206,417 | 9,228,349 |
| Aaron Fletcher | 12,555,043 | 113,076 | 9,228,349 |
| Cameron Gray | 12,594,641 | 73,478 | 9,228,349 |
| Tamar Howson | 12,636,620 | 31,499 | 9,228,349 |
| Peter Kiener | 12,552,191 | 115,928 | 9,228,349 |
| Frank Morich | 9,232,310 | 3,435,809 | 9,228,349 |
| Daniel R. Passeri | 12,619,868 | 48,251 | 9,228,349 |
Auditor Ratification Results:
- For: 21,760,723
- Against: 38,286
- Abstain: 97,459
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Frederick Driscoll and Frank Morich received significantly higher "Withheld" votes compared to other nominees, indicating potential shareholder dissent regarding these specific directors.
- Broker non-votes were substantial (9,228,349) for all director elections, which may impact the effective voting power of beneficial owners.
- RSM US LLP was overwhelmingly ratified as the independent auditor for the 2021 fiscal year.
- The company maintains its status as an emerging growth company.